Rethinking the Annual Physical: What the Evidence Actually Supports
The yearly battery of labs and scans feels thorough — but a 2025 review argues indiscriminate testing can do more harm than good. Here's what targeted, evidence-based screening looks like for a busy adult.
The annual physical has the comforting weight of ritual. You block the calendar, roll up a sleeve, hand over a tube of blood, and leave with the vague sense that something useful has been done. But a 2025 practical guide synthesizing the recommendations of the United States and Canadian preventive-care task forces makes an uncomfortable case: much of what happens during a routine yearly checkup is not supported by evidence that it improves the outcomes patients actually care about — and some of it can quietly cause harm.
The argument is not that prevention doesn't work. It is that prevention works when it is targeted. Running comprehensive labs, imaging, and screenings on asymptomatic adults every year — the default at many concierge clinics and executive-health programs — is, according to the review, not associated with reductions in morbidity or mortality and may produce overdiagnosis and overtreatment instead. The reviewers' alternative is less theatrical but more defensible: a checkup built around the specific tests that high-quality evidence says move the needle for someone of your age, sex, and risk profile.
For a reader optimizing energy, focus, and longevity on a packed calendar, the implication is practical. The goal of your yearly visit isn't to maximize the number of data points collected. It is to ask, deliberately, which decisions this visit should inform — and to order the tests that inform them.
- More is not better. Indiscriminate annual labs and imaging in healthy adults are not linked to improved patient outcomes and can cause harm.
- Overdiagnosis is the hidden cost. Incidental findings on broad screening can trigger biopsies, anxiety, and treatments for conditions that would never have caused symptoms.
- Targeted screening is the standard. Major preventive-care bodies in the US and Canada recommend a defined, age- and risk-adjusted menu — not an all-of-the-above panel.
- Bring a question, not a wishlist. The most useful visit starts with what decisions you need data to support, then orders only the tests that change those decisions.
- This is a synthesis, not a prescription. A clinician who knows your history is the right person to translate guidelines into your specific plan.
The case for restraint: a shorter, sharper checklist tends to outperform a maximalist panel.
Why "thorough" can backfire
The intuition behind a comprehensive annual workup is that catching anything early must be better than catching it late. In some diseases, for some populations, that is true — and those are precisely the screenings the major task forces endorse. The problem is what happens when you screen broadly in people at low baseline risk.
Two effects compound. First, with enough tests, a healthy person will eventually produce an abnormal result by chance alone, prompting follow-up scans, specialist referrals, and sometimes invasive procedures that carry their own risks. Second, sensitive imaging can detect small abnormalities — nodules, cysts, slow-growing lesions — that would never have progressed to cause symptoms in the person's lifetime. Once seen, they are difficult to un-see, and the workup that follows is rarely benign. The 2025 review names this pattern directly, warning that the indiscriminate annual review can result in harm, including overdiagnosis and overtreatment.
The evidence rating here is moderate, not definitive. The reviewers are synthesizing the positions of regulatory bodies — chiefly the US Preventive Services Task Force and the Canadian Task Force on Preventive Health Care — rather than reporting a single trial. But the convergence of two independent national bodies on a restrained, targeted approach is itself signal worth weighing.
The goal of your yearly visit isn't to maximize data collected. It's to identify the decisions you need data to support — and order the tests that inform them.
What a targeted checkup looks like
The review's reframing is less about which tests to drop than about how to choose. A targeted checkup begins with the patient's age, sex, family history, and lifestyle risk factors, and then maps those inputs to the screenings for which high-quality evidence shows benefit — measures the reviewers describe as the ones currently recommended and supported by scientific evidence from the main regulatory authorities.
In practice, that tends to mean a short list executed well: blood pressure measurement, evidence-based cancer screenings at the recommended ages and intervals, lipid and glucose assessment when indicated by risk, immunizations, and counseling on the behaviors that drive the largest share of preventable disease — tobacco, alcohol, physical activity, sleep, and diet. It tends not to mean annual whole-body MRI, broad tumor-marker panels in asymptomatic adults, or imaging "just to have a baseline."
The specifics of which screenings apply to you are exactly the conversation a yearly visit is designed for. The review is a map of what the evidence supports in general; your clinician is the person who knows where you are on it.
A modern checkup is less a single battery of tests than a rolling, risk-adjusted schedule.
How to use this at your next visit
If you have twenty minutes with a physician once a year, the highest-leverage use of that time is rarely to read a longer panel of numbers. It is to make sure the screenings you are due for actually happen, that risk factors you can change are named honestly, and that any new symptoms get the workup they deserve.
A few questions worth bringing in:
- Which screenings am I due for this year, and which can wait? Many evidence-based screenings are not annual.
- What would change in my care if this test came back abnormal? If the answer is "nothing," the test may not be worth the downstream risk.
- What are my top two modifiable risks? Behavioral counseling is one of the most consistently endorsed elements of the periodic exam.
- If something incidental shows up, what's our threshold for acting on it? Agreeing in advance reduces reactive over-treatment.
None of this is an argument against preventive care. It is an argument for preventive care that earns its place. The annual physical, rebuilt around the evidence, is shorter, sharper, and more honest about its limits — and, for a reader trying to spend attention where it counts, that is the version worth keeping on the calendar.
Frequently asked questions
If annual physicals are so common, why does the evidence suggest they may not be as useful as assumed?
According to the 2025 review synthesizing recommendations from major US and Canadian preventive-care bodies, running comprehensive labs, imaging, and screenings on asymptomatic adults every year is not associated with reductions in morbidity or mortality. The review argues that prevention works when it is targeted — matched to a person's age, sex, and risk profile — rather than applied as a blanket all-of-the-above panel.
What is overdiagnosis, and why is it considered a hidden cost of broad screening?
Overdiagnosis occurs when sensitive imaging detects small abnormalities — nodules, cysts, or slow-growing lesions — that would never have progressed to cause symptoms in a person's lifetime. Once seen, these findings are difficult to un-see, and the workup that follows can include biopsies, anxiety, and treatments that carry their own risks, even for conditions that posed no real threat.
What does a targeted, evidence-based checkup actually include?
The article describes a targeted checkup as typically including blood pressure measurement, evidence-based cancer screenings at recommended ages and intervals, lipid and glucose assessment when indicated by risk, immunizations, and counseling on behaviors like tobacco use, alcohol, physical activity, sleep, and diet. It generally does not include annual whole-body MRI, broad tumor-marker panels in asymptomatic adults, or baseline imaging.
What questions should I bring to my next annual visit to get the most out of it?
The article suggests asking which screenings you are due for this year and which can wait, what would change in your care if a given test came back abnormal, and what your top two modifiable risk factors are. It also recommends agreeing in advance on a threshold for acting on any incidental findings, to reduce the chance of reactive over-treatment.
Should I be concerned if a clinic offers comprehensive annual scans or whole-body imaging as part of a routine package?
The article advises caution with programs marketing comprehensive annual scans, broad tumor-marker panels, or whole-body imaging to asymptomatic adults as routine care, noting that the 2025 review is explicit that indiscriminate testing has not been shown to improve outcomes that matter to patients and can cause harm. It notes that such tests are not necessarily never appropriate, but the case for them should rest on individual risk rather than a package offering.
Join the conversation
Comments are moderated and reviewed before they appear. Be constructive — this is health information.
Add your comment